

**Prognostic Value of Serum Ferritin In Chronic
Hepatitis C Patients Receiving Pegylated Interferon
And Ribavirin Combination Therapy**

Thesis

**Submitted for partial fulfillment of Master Degree in
Internal medicine**

By

Esraa Mohamed Ibrahim

(M.B.B.Ch.)

Faculty of medicine Ain shams university

Under supervision of:

Prof. Dr.Mohamed Marei Makhoulf

Professor of Internal medicine
Faculty of medicine Ain shams university

Prof.Dr.Mansour Nasef Mohamed

Professor of internal medicine
Faculty of medicine Ain shams university

Dr.Amir Helmy Samy

Assistant professor of internal medicine
Faculty of medicine Ain shams university

Faculty of medicine
Ain Shams university

2014

بسم الله الرحمن الرحيم

اقرأ باسم ربك الذي خلق ﴿١﴾ خلق
الإنسان من علق ﴿٢﴾ اقرأ وربك
الأكرم ﴿٣﴾ الذي علم
بالقلم ﴿٤﴾ علم الإنسان
ما لم يعلم ﴿٥﴾

صدق الله العظيم

سورة العلق
الآيات (١-٥)

LIST OF CONTENTS

Title	Page No.
Introduction	1
Aim of work	3
Review of literature	4
Chapter 1: Hepatitis C virus	4
Chapter 2 : Management of HCV infection.....	24
Chapter 3: Serum iron and ferritin in chronic hepatitis C	82
Patients and Methods	89
Results	97
Discussion	115
Summary	124
Conclusion & Recommendation.....	126
References	127
Arabic summary.....	--

LIST OF TABLES

Tab. No.	Title	Page No.
Table (1) :	Commonly used staging systems for fibrosis ...	14
Table (2) :	Factors Associated with Progression of Hepatic Fibrosis in Patients with Chronic HCV Infection	35
Table (3) :	Interpretation of HCV Assays	387
Table (4) :	Reasons to Perform a Liver Biopsy in a Patient with Hepatitis C	40
Table (5) :	Is hak System for Fibrosis stage	90
Table (6) :	Demographic and baseline characteristics of all patients in the study(group1).	98
Table (7) :	Multivariate analysis of variables with rapid virological responders (RVR) Vs non RVR	199
Table (8) :	Multivariate analysis of variables associated with early virological responders (EVR) Vs non EVR.	100
Table (9) :	Correlation between serum ferritin levels at week 0, week 4 and week 12 of treatment to different variables at different stages of treatment (using spearman correlation test).....	102
Table (10) :	Correlation between serum ferritin levels at week 0, week 4 and week 12 of treatment with liver biopsy results.....	103

LIST OF TABLES (Cont.)

Tab. No.	Title	Page No.
Table (11):	Correlation between serum rapid and early virological response with liver biopsy results .	104
Table (12):	Comparison between EVR and non EVR as regard fibrosis stage in liver biopsy.	104
Table (13):	Comparison between EVR and non EVR as regard HAI stage in liver biopsy.....	105
Table (14):	Comparison between ferritin level changes during treatment in early virological responders VS.non-responders using Wilcoxon Signed Ranks test.....	106
Table (15):	Analysis of the cutoff value.....	113

LIST OF Figure.

Fig. No.	Title	Page No.
Fig. (1) :	Hepatitis C virus in Egypt compared to other countries in the world is shown below in the graph.	5
Fig. (2) :	Natural history of HCV	7
Fig. (3) :	The Hepatitis C Virus (HCV) Lifecycle (<i>Pawlotsky and Gish., 2006</i>).....	9
Fig. (4) :	: The classic histologic triad of chronic hepatitis C. (A) a portal tract with a lymphoid aggregate. (B) another lymphoid aggregate (<i>arrowheads</i>) with a damaged bile duct (<i>arrow</i>). (C) a portal tract containing a lymphoid follicle with <i>arrowheads</i> delineating the germinal center. Lymphoid follicles are not as commonly seen as lymphoid aggregates. (D) steatosis.....	11
Fig. (5) :	Sources of Infection for Persons with Hepatitis (* haemodialysis, health care workers, perinatal) (CDC, 2008)	17
Fig. (6) :	LP(<i>sanjaya K 2011</i>)	31
Fig. (7) :	Linchen planus(LP) (<i>schwartz 2006</i>)	31
Fig. (8) :	PCT. Erosive erythematous patches, bullae, and milia on the dorsal side of right hand (<i>Sanjaya K, et al 2011</i>)	32

LIST OF Figure (Cont.)

Fig. No.	Title	Page No.
Fig. (9) :	Interferon action in the body.....	47
Fig. (10) :	Chemical structure of ribavirin. (From Copegus [ribavirin, USP] [package insert]. Roche Laboratories Inc, Nutley, New Jersey, 2004.) ..	49
Fig. (11) :	Response to pegylated interferon and ribavirin.	59
Fig. (12) :	Interferon therapy after LDLT	66
Fig. (13) :	Evolution of HCV therapy.....	68
Fig. (14) :	Therapeutic target in new direct antiviral drugs	73
Fig. (15) :	New direct anti viral drugs	73
Fig. (16) :	Compiations for CHC treatment.....	74
Fig. (17) :	Efficacy of sofosbuvir+ alf/RBV	81
Fig. (18) :	Show comparison between serum ferritin at wk 0,4,12 in all patient of the study	107
Fig. (19):	Shows comparison of pretreatment s.ferritin in rapid responders after 4 wks(RVR) and non rapid responders(non RVR)	108
Fig. (20):	Shows comparison of serum ferritin at wk 4 between RVR and non RVR.....	109

LIST OF Figure (Cont.)

Fig. No.	Title	Page No.
Fig. (21) :	Shows comparison of pretreatment serum ferritin in early responders and non early responders (non EVR).....	110
Fig. (22) :	Shows comparison of serum ferritin at wk 4 between EVR and non EVR	111
Fig. (23) :	Shows comparison of serum ferritin at wk 12 between EVR and non EVR	112
Fig. (24) :	ROC curve analysis showing the diagnostic performance of Value of pretreatment level of ferritin for discriminating early virological responders from non-responders	113
Fig. (25) :	Comparison between EVR and non EVR as regard HAI stage in liver biopsy	114

INTRODUCTION

Chronic hepatitis c is an important liver disease , which may progress to cirrhosis or hepatocellular carcinoma. (Sener et al., 2012)

Hepatitis C is the principal cause of death from liver disease and the common leading indication for liver transplantation, some calculations suggest that mortality related to HCV infection (death from liver failure or hepatocellular carcinoma) will continue to increase over the next two decades(*Deuffic-Burban et al.,2007*)

Pegylated interferon (PEG-IFN) and ribavirin combination therapy is the current standard treatment for chronic hepatitis c infection (**Norihisa et al., 2010**)

Several virus and host related predictors of treatment response are known, such as HCV genotype, baseline viral load, age, body weight, race, gender, liver histology, baseline gamma glutamyl transferase level, baseline alanine aminotransferase level and insulin resistance. (*E.Lukasiewicz et al.,2010*).

Iron is an essential substrate for the growth of all organisms, and may facilitate viral replication. Iron may act in synergism with hepatitis C virus (HCV) to accelerate the

progression to cirrhosis and liver carcinoma. It has been previously observed that serum iron indices, and liver iron deposition are frequently raised in patient with chronic viral hepatitis. (*Distante et al.,2002*).

Many recent studies suggested a new predictors of therapeutic response to IFN therapy as serum iron and serum ferritin. However the correlation between serum ferritin level and therapeutic response to IFN and RBV combination therapy remain controversial.(*Norihisa et al;2010*)

AIM OF THE WORK

In this study we aimed to evaluate the relationship between serum ferritin and response to pegylated interferon & ribavirin combination therapy in Egyptian patient with chronic hepatitis C infection .

Chapter 1

Hepatitis C Virus

A) Prevalence of HCV

The World Health Organization has declared hepatitis C a global health problem, with approximately 3% of the world's population (roughly 170-200 million people) infected with HCV. In the US, approximately 3 million people are chronically infected, many of whom are still undiagnosed. (Zaniab et al., 2006).

In Egypt the situation is quite worse the current population in Egypt is about 78 to 80 million. 14.7% of this population (0.147×78 million) is 11,466,000 persons who have been infected with this virus. This number is an underestimate because it does not include the number of people who have been infected that are under 15 years of age or over 60 years of age. Not everyone remains infected but Egypt Demographic and Health Survey (EDHS) reported that 9.8% continue to have HCV RNA. That means almost 10% of the total population are infected and are infectious to other people. That is 7.8 million people with chronic active HCV infection. The issue of treatment for those that develop HCV related liver disease is essentially a medical care crisis for the country.

Transmission of HCV from person to person in Egypt is of course continuing. It has been estimated that an over all 6/1000 new infections each year. In terms of absolute numbers of people in Egypt getting infected this over 500,000 individuals. 70,000 of them are children. This is a public health emergency. (El-Zanaty, et al. 2009. Egypt Demographic and Health Survey)




Fig. (1): Hepatitis C virus in Egypt compared to other countries in the world is shown below in the graph.

El-Zanaty, Fatma and Ann Way. 2009. Egypt Demographic and Health Survey. Cairo, Egypt: Ministry of Health.

In Egypt, the major risk factor associated with HCV infection is a history of antischistosomal injection treatment

before 1986. Schistosomiasis used to be a common parasitic disease in Egypt acquired through swimming or wading in contaminated irrigation channels or standing water. Thus, farmers and rural populations were at greatest risk, and this is supported by the higher prevalence rate of HCV in the Nile delta and rural areas. Schistosomiasis can lead to urinary tract or liver damage over many years. Prior to 1986 the mainstay of treatment was intravenous tartar emetic. Widespread treatment campaigns were carried out in the countryside of Egypt in the 60's-70's and early 80's. At the time of availability of only glass syringes, needles were routinely inadequately sterilized by boiling due to time restraints and limited resources. Overall, despite improvement in schistosomiasis - related morbidity between 1980-1990, these treatment campaigns set the stage for the current large hepatitis (Zainab et al., 2006)

B) Natural history of HCV infection:

The natural history of chronic HCV infection varies greatly and is only partially understood. An average of 60% to 70% of infections lead to a chronic carrier state; 10% to 20% of chronic carriers develop liver cirrhosis, and 1% to 5% develop hepatocellular carcinoma. Older age at time of infection, male gender, diabetes, alcohol use, and co-infection with HIV or HBV appear to increase the risk of progressive liver disease. (fariba, 2010)

STORY AND PROGNOSIS OF HCV




Fig (2) : Natural history of HCV